Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

AN AREA of Scotland has been revealed as a world hotspot for Huntington’s disease. New research has revealed the shockingly ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The good news? You don’t need to be a scientist to protect yourself from hype and heartbreak. So, HDBuzz has Ten Golden Rules ...

Qure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing ...

Shawn Kortes, known for his philanthropic work in the community, started dialysis this year and is searching for a kidney ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is ...

Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.

Shares of uniQure N.V. (NASDAQ:QURE) surged 39% following the announcement that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to AMT-130, its gene therapy ...

Qure (QURE) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AMT-130 for the treatment ...